Analysis of the reasons why the domestic launch of Elacetrant has been delayed many times

The domestic launch of elacestrant (Elacestrant) has been repeatedly delayed, mainly related to the drug approval process and registration review requirements. First of all, elastran is an oral selective estrogen receptor degrader (SERD), targeting breast cancer patients, especially estrogen receptor-positive (ER+) and HER2-negative breast cancer groups. Because its mechanism of action is a precision-targeted drug, the domestic Food and Drug Administration has high requirements for clinical data, efficacy evidence, and safety during drug registration and approval. Pharmaceutical companies are required to provide sufficient multi-center clinical trial data to verify its efficacy and tolerability in the Chinese population. This results in a relatively long approval cycle, which affects the original time to market.

Secondly, the discrepancy between international clinical trial data and the domestic patient population is also a factor in the delay in marketing. The initial key data on elastran came from European and American patient populations, and Chinese patients may have differences in genetic background, drug metabolism, and comorbid diseases. In order to ensure the safety and effectiveness of drugs in the country, drug regulatory authorities usually require additional localized clinical trials or analytical data for Asian populations. This requirement increases the clinical research burden on companies and prolongs market preparation time.

Third, domestic drug launches involve price negotiations and the alignment of medical insurance policies, which may also affect the pace of launches. Although elastran has not yet been included in medical insurance, when pharmaceutical companies are preparing to submit marketing applications, they usually need to conduct a pre-assessment of price strategies, channel layout, and possible future coverage by medical insurance. While ensuring the commercial viability and patient accessibility of drugs, companies also need to meet the compliance requirements of regulatory authorities, which to a certain extent will also delay the time to market.

Finally, production technology and drug quality control are also key factors. Elastran is a high-end oral small molecule targeted drug. The production process has strict requirements on the purity of the raw material, the stability of the preparation and the consistency of the drug. If technical difficulties arise in quality control, process verification or large-scale production, the launch of the drug will also be delayed. In addition, as the domestic Food and Drug Administration gradually tightens the review of new drugs, companies need to spend more time in submitting registration materials, clinical data verification and quality verification, resulting in multiple delays in launch time.

Reference materials:https://www.drugs.com/